Navigation Links
Third FDA Clearance for Revolutionary Simbionix Product

CLEVELAND, March 29, 2013 /PRNewswire/ --

Simbionix USA Corporation, the world's leading provider of medical education and simulation training, has received FDA clearance for its TEVAR (Thoracic Endovascular Aneurysm Repair) application for PROcedure Rehearsal Studio™ (PRS). This application joins the family of PRS cleared for marketing applications for Carotid Intervention and EVAR (Endovascular Aneurysm Repair) procedures.


TEVAR is an emerging treatment modality, which has been rapidly embraced by clinicians treating thoracic aortic disease. It is a far less invasive approach than open surgery. Additionally, the availability and relative ease of application with TEVAR has changed and extended management options in thoracic aortic disease, including in patients deemed unsuitable for open surgery. The skills necessary to perform TEVAR require dedicated formal training, as this procedure requires considerable perceptual, cognitive and psychomotor demands on the surgeons.

The PROcedure Rehearsal Studio utilizes revolutionary technology, developed by Simbionix, allowing physicians to rehearse a complete endovascular procedure on a virtual 3D anatomical model based on a specific patient's CT data. The virtual model may then be used for the purpose of simulating, analyzing and evaluating preoperative surgical treatment options prior to performing the actual procedure, which may increase physician's confidence in the upcoming procedure. Once the 3D model has been exported to the Simbionix ANGIO Mentor™ simulation environment, the physician can practice numerous times to evaluate different techniques, while using true-to-life tools and endografts.

The Society of Vascular Surgery suggests that surgeons perform a minimum of 100 diagnostic, 50 interventional and 10 TEVAR cases to become certified. With this new innovative application, physicians can actually receive hands-on training in TEVAR procedures, including precise deployment of single and multiple stent grafts, as well as touch-up ballooning, before operating on a live patient. The PRS simplifies procedure planning, and provides a comprehensive solution for training and simulation of patient specific procedures aimed to enhance the professional level of both experienced and novice physicians.

According to Dr. Yael Friedman , Director of Regulatory Affairs for Simbionix, the Simbionix track record in providing healthcare professionals with innovative simulation tools is the foundation of yet another successful product. "Thoracic Endovascular Aneurysm Repair is one of the most advanced medical procedures that endovascular surgeons perform. Simbionix is extremely pleased to have received the FDA clearance and proud of our new PROcedure Rehearsal Studio clinical TEVAR application which will help clinicians in analyzing and evaluating preoperative surgical treatment options."

Simbionix USA Corporation is the world's leading provider of simulation, training and education products for medical professionals and the healthcare industry. The company is committed to delivering high quality products, advancing clinical performance and optimizing procedural outcomes.

Visit:   FacebookTwitter and LinkedIn.

Contact: Rebecca Levy , Manager of Marketing Communications, at, +1-216-2292040

SOURCE Simbionix USA Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
2. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
3. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
4. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
5. Cardica Announces Fiscal 2012 Third Quarter Financial Results
6. Hill-Rom Announces Third Quarter 2012 Dividend
7. Cardinal Health Reports Third-Quarter Results
8. TPI to Host Third Quarter of Fiscal Year 2012 Earnings Conference Call on Tuesday, May 15, 2012 at 9:00 a.m. ET
9. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
10. ThermoGenesis Corp. To Announce Third Quarter Fiscal 2012 Results On May 10, 2012
11. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
Post Your Comments:
(Date:11/24/2015)... LONDON , November 24, 2015 ... PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and ... areas are going to grow at the fastest rates? ... to 2025, assessing data, trends, opportunities and prospects there. ... graphs. Discover the most lucrative areas in the industry ...
(Date:11/24/2015)... , UAE, November 24, 2015   ... and dietician deliver s advice and ...   More than 50% of ... to keep themselves healthy according to the DHA   femMED ... in the UAE    Dubai residents are not ...
(Date:11/24/2015)... , Nov. 24, 2015  Eyewear brand Revo ... collaboration with U2 lead singer and activist Bono as part ... prevent vision impairment and blindness in more than 5 million ... Revo will donate $10 from the sale of every ... up to a total of $10 million to the "Buy ...
Breaking Medicine Technology:
(Date:11/24/2015)... Los Angeles, CA (PRWEB) , ... November 24, 2015 , ... ... author explored the different restrictions and variables that determine which patients are or are ... are those patients that have a BMI over 40, are more than 100 pounds ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five seconds to ... that the first impression be positive and reflects business values. If a client starts ... or want to return. They will also share their thoughts about a business with ...
(Date:11/24/2015)... ... November 24, 2015 , ... Cancer patients, survivors, caregivers, ... at a live taping of the next CURE Connections® video series ... Cancers 2015 Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding ... an innovative study designed to yield insights into how to detect and treat pancreatic ... for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that is present ...
(Date:11/24/2015)... ... 24, 2015 , ... Sir Grout of Baltimore is proud ... The award recognizes good companies for excellence in service and a commitment to ... hard surface restoration company earned this recognition after a thorough review by the ...
Breaking Medicine News(10 mins):